Efficacy and outcomes of Lian-Hua Qing-Wen capsule in the treatment of novel coronavirus pneumonia (COVID-19): a medical records based retrospective study
Not Applicable
Recruiting
- Conditions
- ovel coronavirus disease (COVID-19)
- Registration Number
- ITMCTR2000003537
- Lead Sponsor
- 920th Hospital of the PLA Joint Logistics Support Force
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Patients who were aged 18 years or older and laboratory-confirmed with COVID-19 by nucleic acid assay
Exclusion Criteria
1. Missing pathogen or chest computerized tomography (CT) detection;
2. Severe comorbidities, such as advanced malignancy, congenital heart disease or autoimmune diseases.
Study & Design
- Study Type
- Observational study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Lian-Hua Qing-Wen capsule's antiviral activity against SARS-CoV-2?
How does Lian-Hua Qing-Wen capsule compare to standard-of-care treatments for mild-to-moderate COVID-19 in clinical outcomes?
Which biomarkers correlate with improved prognosis in patients treated with Lian-Hua Qing-Wen for viral pneumonia?
What adverse events are associated with Lian-Hua Qing-Wen capsule in respiratory viral infections and how are they managed?
Are there synergistic effects when combining Lian-Hua Qing-Wen with other antiviral agents like remdesivir in treating SARS-CoV-2 infections?